Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer

BACKGROUND: The combination of immune checkpoint inhibitors (ICIs) and chemotherapy is known to improve overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC). ICIs have different response patterns and survival kinetics characteristics from those of the traditional c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shuang, Li, Shuang, Cui, Yanan, Zhao, Peiyan, Sun, Xiaodan, Cheng, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316832/
https://www.ncbi.nlm.nih.gov/pubmed/34336683
http://dx.doi.org/10.3389/fonc.2021.696010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316832/
https://www.ncbi.nlm.nih.gov/pubmed/34336683
http://dx.doi.org/10.3389/fonc.2021.696010

Ejemplares similares